全球恶性间皮瘤市场规模、份额、成长分析，按应用（医院药房、零售药房）、按类型（口服、肠胃外）- 2024-2031 年行业预测

2022年全球恶性间皮瘤市场规模为1.5393亿美元，预计将从2023年的1.627亿美元增长到2031年的2.5351亿美元，预测期内（2024-2031年）复合CAGR为5.7%。

间皮瘤患者的倡议团体和支持网络是全球对抗这种癌症的关键支柱。他们的努力有助于提高认识、促进早期发现，并为患有间皮瘤的个人提供重要支持。这些组织透过其宣传、教育措施和外展计划发挥着不可或缺的作用，显着改善了病患照护。透过向受疾病影响的人提供援助和资源，他们在减轻患者在困难道路上所面临的负担方面发挥关键作用。

目录

执行摘要

• 市场概况
• 命运之轮

研究方法论

• 资讯采购
• 二手和主要资料来源
• 市场规模估计
• 市场假设与限制

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战

主要市场洞察

• 技术分析
• 定价分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• 启动分析
• 原料分析
• 创新矩阵
• 管道产品分析
• 总体经济指标
• 顶级投资分析
• 成功的关键因素
• 竞争程度

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战
• 监管环境
• 波特分析
• 对未来颠覆的特别见解

全球恶性间皮瘤市场（按应用）

• 市场概况
• 医院药房
• 零售药局
• 肿瘤中心
• 其他的

全球恶性间皮瘤市场（按类型）

• 市场概况
• 口服
• 注射用

全球恶性间皮瘤市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • MEA 的其余部分

竞争格局

• 前 5 名玩家比较
• 2021 年关键参与者的市场定位
• 主要市场参与者所采取的策略
• 最佳制胜策略
• 近期市集活动
• 主要公司市占率（%），2021年

主要公司简介

• AstraZeneca
• Bristol-Myers Squibb
• Roche
• Merck
• Novartis
• Pfizer
• Sanofi
• Eli Lilly
• Teva Pharmaceuticals
• Boehringer Ingelheim GmbH
• Mylan
• Fresenius Kabi
• Sun Pharmaceuticals
• Corden Pharma
• Concordia International
• Kyowa Hakko Kirin
• Polaris Pharmaceuticals
• MolMed
• Ono Pharmaceutical
• Nichi-Iko Pharmaceutical

Global Malignant Mesothelioma Market size was valued at USD 153.93 million in 2022 and is poised to grow from USD 162.70 million in 2023 to USD 253.51 million by 2031, growing at a CAGR of 5.7% in the forecast period (2024-2031).

Advocacy groups and support networks for mesothelioma patients serve as crucial pillars in the worldwide battle against this form of cancer. Their efforts are instrumental in raising awareness, promoting early detection, and furnishing vital support to individuals grappling with mesothelioma. These organizations fulfill an indispensable role through their advocacy, educational initiatives, and outreach programs, significantly enhancing patient care. By offering assistance and resources to those affected by the disease, they play a pivotal role in easing the burdens faced by patients on their difficult path.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malignant Mesothelioma Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malignant Mesothelioma Market Segmental Analysis

The global malignant mesothelioma market is segmented into three major segments i.e. by type, application, region. Based on type the market is segmented as, oral, parenteral. Based on application the market is segmented as, hospital pharmacies, retail pharmacies, oncology centers, other. Based on region the market is segmented as, North America, Europe, Asia-Pacific, MEA, and Latin America.

Drivers of the Malignant Mesothelioma Market

The surge in advancements in diagnostic methodologies plays a pivotal role in the detection of malignant mesothelioma cases. Significant enhancements in diagnostic techniques and tools have been witnessed over time, contributing to the early identification and diagnosis of this cancer. These improvements, coupled with heightened awareness among healthcare professionals and the public, have facilitated early detection and diagnosis, resulting in a higher reported incidence of cases at earlier stages.

Restraints in the Malignant Mesothelioma Market

A notable constraint in this context is the extended duration taken for diagnosis, which can impede timely intervention. Malignant mesothelioma is characterized by a prolonged latency period, often spanning several decades from initial asbestos exposure to symptom manifestation. This lengthy timeline poses a considerable challenge, delaying early diagnosis and intervention for individuals at risk.

Market Trends of the Malignant Mesothelioma Market

One of the key trends influencing the market is the aging population, which significantly contributes to the rising incidence of malignant mesothelioma. The cancer is more prevalent among older demographics, and with the global population aging, the likelihood of new cases is expected to increase. Moreover, the extended latency period for mesothelioma means that individuals exposed to asbestos earlier in life may develop the disease as they age.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Malignant Mesothelioma Market by Application

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Oncology Centers
• Others

Global Malignant Mesothelioma Market by Type

• Market Overview
• Oral
• Parenteral

Global Malignant Mesothelioma Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corden Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Concordia International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Hakko Kirin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MolMed
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nichi-Iko Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments